The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; BMS Brazil; Boehringer Ingelheim; MSD; Pierre Fabre; Roche
Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo).
 
Jaafar Bennouna
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Roche
 
Javier De Castro
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Roche
 
Anne-Marie C. Dingemans
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Clovis Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Pfizer; Roche/Genentech (Inst)
 
Frank Griesinger
Honoraria - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Celgene; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche
 
Francesco Grossi
No Relationships to Disclose
 
Corey J. Langer
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck
Research Funding - Advantagene (Inst); Ariad (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Stem CentRx (Inst)
 
Yuichiro Ohe
Stock and Other Ownership Interests - Ono Pharmaceutical (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Lilly Japan; MSD; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Kyorin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - AstraZeneca
 
Konstantinos N. Syrigos
No Relationships to Disclose
 
Nick Thatcher
Honoraria - Amgen; Boehringer Ingelheim; Celgene; Lilly; Roche
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Lilly; Roche
Speakers' Bureau - Amgen; Boehringer Ingelheim; Lilly; Roche
 
Ashis Das-Gupta
Employment - Roche
 
Margarita Donica
Employment - Roche
Stock and Other Ownership Interests - Novartis
 
Vlatka Smoljanovic
Employment - Roche
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Roche
 
Cesare Gridelli
Consulting or Advisory Role - BMS Brazil; Celgene; MSD; Novartis; Roche
Speakers' Bureau - BMS Brazil; Celgene; MSD
Research Funding - Lilly
Travel, Accommodations, Expenses - BMS Brazil; Celgene; MSD